Morgan Stanley has sharply increased its year-end target for the KOSPI index to 6,500 points, marking a 25% surge from its previous 5,200-point target set just last month. The investment bank attributes this optimistic outlook to a robust and sustained AI memory semiconductor supercycle and a more favorable domestic policy landscape in South Korea. In an even more bullish scenario, Morgan Stanley suggests the KOSPI could reach as high as 7,500 points, particularly encouraging investors to focus on the first half of the year for peak performance. This upgrade comes after the MSCI Korea Index has already seen a 34.9% increase year-to-date in 2026, leading global markets in dollar terms.
The core drivers behind this target elevation include substantial upward revisions in earnings estimates, predominantly led by technology stocks, especially semiconductors. Morgan Stanley specifically raised its target price for Samsung Electronics from 210,000 won to 248,000 won, emphasizing that the AI-driven memory cycle is stronger and more enduring than initially anticipated, with infrastructure investment unlikely to decelerate. Consensus net profit estimates for 2026 have been revised up by 38.5% since the beginning of the year, with the IT sector contributing a dominant 82.9% of these upgrades. Consequently, Morgan Stanley forecasts an impressive 88% year-over-year aggregate net profit growth for the KOSPI in 2026.
While expressing strong optimism, Morgan Stanley also flagged potential risks. The report warns that a slowdown in earnings upgrades, particularly within the IT and industrial sectors, could trigger a market correction. A decrease in semiconductor earnings momentum, in particular, would pose a significant burden on the KOSPI. The bank also noted that the possibility of reaching the 7,500-point bull-case scenario appears higher in the first half of the year, as macroeconomic uncertainties, geopolitical conflicts, and policy-related issues could intensify in the latter half. Despite these warnings, the overall sentiment remains highly positive, bolstered by expanding market liquidity and ongoing capital market reforms.
In terms of sector-specific adjustments, Morgan Stanley upgraded its view on the healthcare sector to 'Overweight' and downgraded the non-bank financial sector to 'Neutral'. A notable strategic move was the inclusion of Samsung Biologics (207940) in its Focus List, with expectations of a 17% increase in Q1 revenue and a 26% rise in operating profit year-over-year. This is supported by the acquisition of a U.S. plant and securing new contracts valued at 1.2 trillion won (approximately $837 million).
